Health care stocks were edging higher premarket Tuesday with the iShares Biotechnology ETF (IBB) advancing by 0.8% and the Health Care Select Sector SPDR Fund (XLV) recently up 0.6%.
Nektar Therapeutics (NKTR) shares were surging by more than 110% after the company said the phase 2b study of investigational rezpegaldesleukin met its primary endpoint in patients with moderate to severe atopic dermatitis.
Amarin (AMRN) shares were up nearly 9% after the company said it signed an exclusive license and supply agreement with Recordati to commercialize Vazkepa in 59 European countries.
Nuvation Bio (NUVB) shares were more than 2% higher after the compay said taletrectinib has been added as a preferred agent in the updated National Comprehensive Cancer Network clinical practice guidelines for non-small cell lung cancer, or NSCLC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.